Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

多西紫杉醇 医学 前列腺癌 雄激素剥夺疗法 肿瘤科 内科学 恩扎鲁胺 比卡鲁胺 泌尿科 前列腺特异性抗原 置信区间 癌症 雄激素受体
作者
Pernelle Lavaud,Gwénaëlle Gravis,Stéphanie Foulon,Florence Joly,Stéphane Marie. Oudard,Frank Priou,I. Latorzeff,Loïc Mourey,Michel Soulie,R. Delva,I. Krakowski,Brigitte Laguerre,Christine Théodore,Jean Marc Ferrero,Philippe Beuzeboc,Muriel Habibian,Frédéric Rolland,G. Deplanque,Damien Pouessel,Sylvie Zanetta
出处
期刊:European Urology [Elsevier BV]
卷期号:73 (5): 696-703 被引量:66
标识
DOI:10.1016/j.eururo.2017.09.022
摘要

Androgen deprivation therapy (ADT) plus docetaxel is the standard of care in fit men with metastatic castration-naive prostate cancer (mCNPC) following results from GETUG-AFU 15, CHAARTED, and STAMPEDE. No data are available on the efficacy of treatments used for metastatic castration-resistant prostate cancer (mCRPC) in men treated upfront with ADT plus docetaxel for mCNPC.To investigate the efficacy and tolerance of subsequent treatments in patients treated upfront with chemo-hormonal therapy for mCNPC.Retrospective data from the GETUG-AFU 15 phase 3 trial were collected for treatments received for mCRPC.For the first three lines of salvage treatment for mCRPC we investigated the biochemical progression-free survival, maximum prostate-specific antigen (PSA) decline, overall survival, and tolerance.Overall, 245 patients received at least one treatment for mCRPC. For docetaxel used in first-line, a PSA decline ≥50% was observed in 25/66 (38%) and in 4/20 patients (20%) who had received upfront ADT alone and ADT plus docetaxel (p=0.14). The median biochemical progression-free survival was 6.0 mo (95% confidence interval: 3.6-7.7) and 4.1 mo (95% confidence interval: 1.3-4.9), respectively. For docetaxel used in first- or second-line, a PSA decline ≥50% was observed in 36/80 (45%) and in 4/29 patients (14%) who had received upfront ADT alone and ADT plus docetaxel (p=0.07). PSA declines ≥50% were observed with bicalutamide in 12/28 (43%) and 4/23 patients (17%) who had received upfront ADT alone and ADT plus docetaxel. Among men treated upfront with ADT plus docetaxel who received abiraterone or enzalutamide for mCRPC, 10/19 patients (53%) achieved a PSA decline ≥50%. Few grade 3-4 events occurred. Study limitations include the observational design and retrospective characteristics of this analysis, without standardized therapeutic salvage protocols, and the limited number of patients in some of the treatment subgroups.Docetaxel rechallenge following progression to mCRPC after upfront ADT plus docetaxel for mCNPC was active only in a limited number of patients. Available data on abiraterone and enzalutamide support maintained efficacy in this setting. The lack of standardized therapeutic protocols for men developing mCRPC limits the comparability between patients.Rechallenging docetaxel at castration-resistance was active only in a limited number of patients treated upfront with chemo-hormonal therapy for metastatic castration-naive prostate cancer. Anticancer activity was suggested with abiraterone or enzalutamide in this setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
4秒前
drleslie完成签到 ,获得积分10
5秒前
Alexlovar发布了新的文献求助30
6秒前
6秒前
凯旋归来完成签到 ,获得积分10
6秒前
6秒前
7秒前
zhanzhanzhan发布了新的文献求助20
7秒前
8秒前
路小雨发布了新的文献求助10
9秒前
蒋莹萱完成签到 ,获得积分10
9秒前
简单的浩然完成签到,获得积分10
10秒前
10秒前
10秒前
wangyuu关注了科研通微信公众号
10秒前
活力孤菱完成签到,获得积分10
11秒前
nxdr发布了新的文献求助10
12秒前
英姑的应助被曾经的路灯采纳,获得10
12秒前
dxt发布了新的文献求助10
12秒前
卡皮巴拉完成签到 ,获得积分10
13秒前
GTR的我完成签到 ,获得积分10
13秒前
等风归发布了新的文献求助10
14秒前
Xy完成签到,获得积分10
14秒前
yu发布了新的文献求助10
14秒前
Akim的应助被饼饼采纳,获得10
15秒前
彭于晏的应助被unicornmed采纳,获得10
15秒前
复杂的悟空完成签到,获得积分10
15秒前
Alexlovar完成签到,获得积分20
16秒前
18秒前
Alicyclobacillus完成签到,获得积分10
19秒前
我爱科研科研爱我完成签到,获得积分10
22秒前
23秒前
小蘑菇的应助被陈小黑采纳,获得10
23秒前
24秒前
ly完成签到,获得积分10
24秒前
25秒前
ref:rain完成签到 ,获得积分10
26秒前
杨淼发布了新的文献求助10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621